# Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia

> **NCT00036257** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 15 (—)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** CP-461

## Key facts

- **NCT ID:** NCT00036257
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03
- **Primary completion:** —
- **Final completion:** 2003-04
- **Target enrollment:** 15 (—)
- **Last updated:** 2011-10-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00036257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00036257, "Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00036257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*